Intermediate risk endometrial cancer- A heterogeneous clinical entity by Rychlik, Agnieszka
1 
CÁNCER DE ENDOMETRIO DE RIESGO INTERMEDIO-         
UNA ENTIDAD CLÍNICA HETEROGÉNEA  
INTERMEDIATE RISK ENDOMETRIAL CANCER-  
A HETEROGENEOUS CLINICAL ENTITY 
TESIS DOCTORAL EN MEDICINA 
AGNIESZKA RYCHLIK 
DIRECTORES DE LA TESIS 
PLUVIO JESÚS CORONADO MARTÍN 
IGNACIO ZAPARDIEL GUTIÉRREZ 
2 
 
TABLE OF CONTENTS 
 
 






2. CLINICAL PRESENTATION AND DIAGNOSIS 
 
3. PATHOLOGICAL AND MOLECULAR CLASSIFICATIONS 
 
4. PREOPERATIVE ASSESSMENT 
 
5. STAGING CLASSIFICATIONS 
 
6. DEFINITIONS OF INTERMEDIATE RISK ENDOMETRIAL CANCER  
 
7. SURGICAL MANAGEMENT OF INTERMEDIATE ANG HIGH INTERMEDIATE ENDOMETRIAL CANCER  
 
8. ADJUVANT TREATMENT OF INTERMEDIATE ANG HIGH INTERMEDIATE ENDOMETRIAL CANCER 
 
9. CONTROVERSIES ON SURGICAL STAGING: THE ISSUE OF LYMPH NODE DISECTION  
 




















TABLES AND FIGURES 
I. Tables 
Table I. Molecular classification of endometrial cancers by histology. 
Table II. Current FIGO 2009 staging classification for cancer of the corpus uteri. 
Table III. FIGO staging compared with the TNM classification. 
Table IV. Risk groups according to ESGO/ESMO/ESTRO 2016 classification. 
Table V. Risk groups according to ESGO 2010 classification. 
Table VI. Definition of Intermediate and High-Intermediate according to ESGO/ESMO/ESTRO 2016. 
Table VII. Patient demographics and pathologic details in intermediate risk endometrial cancers. 
Table VIII. Predictive factors of lymph node metastases in 477 cases of intermediate risk endometrial cancers. 
Table IX: Recurrence and mortality in 477 cases of intermediate risk endometrial cancers. 
Table X. Univariate analysis of disease-free survival and overall survival in 477 intermediate risk endometrial 
cancers. 




Figure 1 A, B. A: Estimated age-standardized cancer incidence rates in 2018, females, all ages,  
B: Estimated number of cancer related deaths in 2018, females, all ages. 
Figure 2 A, B. A: Transvaginal Ultrasound, increased endometrial thickness.  
B: Hysteroscopic image of endometrial cancer. 
Figure 3. Diagnostic algorithm for integrated genomic-pathologic classification of endometrial carcinomas. 
Figure 4 A, B. Representative examples of focal and substantial lymphovascular space invasion. 
Figure 5 Pelvic sentinel lymph node traced with patent blue and indocyanine green. 
Figure 6. Patients’ selection chart. 
Figure 7. High-intermediate and intermediate risk study group.  
Figure 8. Comparison of intermediate risk and high-intermediate risk group. 
Figure 9. Oncological outcome of intermediate and high-intermediate risk.  
Figure 10. A, B. A: Kaplan-Meier estimate of disease-free survival. B: Kaplan-Meier estimate of overall survival 
in intermediate and high-intermediate endometrial cancer.  
Figure 11. Impact of positive lymph nodes on disease-free survival. 
Figure 12. Impact of positive lymph nodes on overall survival. 
Figure 13. Impact of LVSI on disease-free survival. 






Risk models in endometrial cancer define prognosis and indicate adjuvant therapy. The 
currently most used classification was updated in 2016 in collaboration with the European 
Society of Medical Oncology (ESMO), the European Society of Gynecologic Oncology (ESGO) 
and European Society of Radiotherapy (ESTRO). A high-intermediate risk group was 
introduced within the intermediate risk group. The objective of this doctoral thesis is to 
evaluate the clinical relevance of the current subclassification of intermediate risk 




A multicenter retrospective study was carried out at 5 international tertiary 
institutions. Patients diagnosed with intermediate risk endometrial cancer on the basis of 
definitive pathology findings were included. Patients were stratified into intermediate and 
high-intermediate risk groups. Incidence of nodal metastases, disease-free and overall survival 
were compared between the two risk groups in univariate and multivariate analysis. 
 
Results  
Four hundred seventy-seven patients were included. Three hundred twenty-five (68%) 
patients were identified as intermediate and 152 (32%) patients as high-intermediate 
endometrial cancer patients. Nodal metastases were found in 18 patients (11.8%) with high-
intermediate risk endometrial cancer group and 16 patients (4.9%) in intermediate risk group 
(p=0.006). Lymphovascular space invasion (LVSI) was found to be a strong predictive factor of 
lymph node involvement (p<0.001). High-intermediate risk, compared to intermediate risk 
was found to be an independent factor of disease-free survival (hazard ratio: 1.76; 95% 
confidence interval: 1.00-3.08; p=0.050) and overall survival (hazard ratio: 1.99; 95% 




The doctoral thesis results validate the clinical significance of intermediate risk 
endometrial cancer subclassification. Prognosis of high-intermediate risk endometrial cancer 





I. RESUMEN  
Objetivo: 
Los modelos de riesgo en el cáncer de endometrio permiten definir el pronóstico de la 
enfermedad y ayudan en la indicación de la terapia adyuvante. La clasificación más usada 
actualmente fue publicada en el año 2016 en colaboración con la Sociedad Europea de 
Oncología Médica (ESMO), la Sociedad Europea de Ginecología Oncológica (ESGO) y la 
Sociedad Europea de Radioterapia (ESTRO).  
El objetivo de esta tesis doctoral es evaluar la relevancia clínica de la última 
subclasificación del cáncer de endometrio de riesgo intermedio en relación a su asociación 
con la afectación ganglionar y con el pronóstico oncológico. 
 
Métodos 
Se realizó un estudio retrospectivo multicéntrico en 5 instituciones terciarias a nivel 
internacional. Se incluyeron pacientes diagnosticadas de cáncer de endometrio de riesgo 
intermedio sobre la base de los hallazgos anatomopatológicos definitivos de las piezas 
quirúrgicas. Las pacientes se subclasificaron en grupos de riesgo intermedio e intermedio-alto. 
Se comparó la incidencia de metástasis ganglionares, la supervivencia libre de enfermedad  




Se incluyeron 477 pacientes que cumplieron con los criterios establecidos. 325 (68%) 
pacientes se identificaron como casos de riesgo intermedio y 152 (32%) pacientes como casos 
con cáncer de endometrio de riesgo intermedio-alto. Se encontraron metástasis ganglionares 
en 18 pacientes (11,8%) con cáncer de endometrio de riesgo intermedio-alto y en 16 pacientes 
(4,9%) en el grupo de riesgo intermedio (p=0,006). La invasión del espacio linfovascular (LVSI) 
fue un factor predictivo importante de la afectación de los ganglios linfáticos (p< 0,001). En el 
estudio multivariante, el riesgo intermedio-alto fue un factor independiente de supervivencia 
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libre de enfermedad (Hazard ratio: 1,76; intervalo de confianza del 95%: 1,00 a 3,08; p = 0,050) 
y supervivencia global (Hazard ratio: 1,99; intervalo de confianza del 95%: 1,10 -3,60;  
p = 0,022). 
 
Conclusiones 
Este trabajo valida la importancia clínica de la subclasificación del cáncer de endometrio de 
riesgo intermedio. El pronóstico del cáncer de endometrio de riesgo intermedio-alto es 






1. EPIDEMIOLOGY OF ENDOMETRIAL CANCER 
Endometrial cancer is the most common female genital tract neoplasm in the Western 
world. In 2015, around 5,410 new cases were diagnosed in Spain, representing an incidence 
of 5.9 per 100,000 women, with a 5-year prevalence of 7.6 per 100,000 [1]. Regarding world 
incidence, presented in Figure 1, it is the sixth most common cancer in women (4.8% of 
cancers in women) with an estimated incidence of 382,069 cases in 2018. The cumulative risk 
of developing the disease at 75 years is 1.01% [2]. It is the 14th cancer in terms of mortality in 
the world (89,929 deaths) [2]. The cumulative risk of death up to age 75 is 0.2%. In Spain the 
mortality rate is estimated at 3.1 per 100,000 [1]. 
The increase in incidence of endometrial cancer in recent years in Europe and North 
America is probably related to the older age of the population as well as the higher prevalence 
of obesity and metabolic syndrome in these regions. Estimations show that the number of 





Figure 1 A, B. A: Estimated age-standardized cancer incidence rates in 2018, females, all ages, after GLOBOCAN 
2018. B: Estimated number of cancer related deaths in 2018, females, all ages, after GLOBOCAN 2018 [2]. 
 
Although endometrial cancer is traditionally associated with postmenopausal 
bleeding, 14% of cases are diagnosed in premenopausal women, (5% in those under 40 years 
of age) [4]. The main risk factors include exposure to exogenous oestrogens, family or genetic 
risk, obesity, nulliparity, early menarche, late menopause, and the use of tamoxifen. The 
relationship between diabetes mellitus and endometrial cancer remains controversial, as 
obesity is probably a major confounding factor. 
Treatment with Levonorgestrel intrauterine device (IUD), depot progestogens and the 
use of hormonal contraceptives seems to be protective, especially in patients with 
hypoestrogenism secondary to chronic anovulation [5]. 
No screening strategy has been developed for endometrial cancer prevention. This 
concerns as well patients with hereditary non-polyposis colon cancer or Lynch syndrome 
where the efficacy of screening has neither been proven. Prophylactic hysterectomy is 




2. CLINICAL PRESENTATION AND DIAGNOSIS 
Majority of patients (about 90%) presents with abnormal uterine bleeding 
(postmenopausal bleeding, hypermenorrhea or menometrorrhagia). Abnormal vaginal 
discharge or pyometra may also occur. Advanced endometrial cancer may have symptoms 
similar to patients with advanced ovarian cancer such as abdominal pain and distention and 
constitutional symptoms (weight loss, anaemia). Rarely, patients are diagnosed after an 
abnormal cervicovaginal Pap smear result. 
Pelvic ultrasonography is a standard procedure when abnormal uterine bleeding 
occurs (Figure 2A). In case of increased endometrial thickness, endometrial sampling is 
indicated. The cut-off of endometrial thickness is not clear and ranges between 3 and 5 mm 
in postmenopausal women. A review of 13 studies showed that 5 mm endometrial thickness 
cut-off has a sensitivity of 90% and specificity of 54%, compared to 98% and 54% when a 3 
mm cut-off was used [7]. Diagnosis can be made on a basis of simple office Pipelle endometrial 
sampling, which is sufficient for preoperative assessment and treatment planning. When the 
Pipelle biopsy result is inconclusive, hysteroscopy with biopsy is recommended [1] (Figure 2B). 
  
Figure 2 A, B. A: Transvaginal Ultrasound, increased endometrial thickness. B: Hysteroscopic image of 
endometrial cancer. 
3. CLASSIFICATIONS 
A) Histological classifications 
According to classical Federation of Gynecology and Obstetrics (FIGO) classification 
(after Bokhman dualistic model [8]) endometrial cancer is traditionally classified as: 
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• Type 1 – endometrioid, the most common and usually diagnosed at early stages. This 
type presents a relatively good prognosis. It may arise from complex atypical 
hyperplasia. Type 1 is endometrioid, diploid and linked to excess of oestrogen 
stimulation. 
• Type 2 – non-endometrioid, less common and less hormone sensitive. Typically, more 
aggressive, aneuploid, TP53-mutated. It presents a poorer prognosis. 
Within type 1 endometrial cancer, the PIK3CA pathway alterations are frequently observed 
(90% of cases). In 20% of type 1 tumors KRAS mutation is also present. FGFR2 mutations 
are reported in 12% of tumors [9]. 
Type 2 endometrial cancers include a wide range of pathological subtypes and have a 
variety of genomic and molecular features and alterations. Details are represented in table 
I. 
This traditional classification has been currently replaced by endometrioid and non-




 Endometrioid Serous Carcinosarcoma Clear-cell 
Bokhman  
Subtype I II II II 
TP53 mutation Rare  >90 % 60-90% 35% 
































































Table I. Molecular classification of endometrial cancers by histology [9]. 
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Endometrial adenocarcinoma can be also classified according the degree of 
differentiation. Grade 1 comprises less than 5% of a non-squamous or non-morular solid 
growth pattern. Grade 2 is defined as 6%–50% of a non-squamous or non-morular solid 
growth pattern. Grade 3 is characterized by greater than 50% of a non-squamous or non-
morular solid growth pattern. If an important nuclear atypia is present, it may increase the 
grade of tumor. Serous and clear-cell carcinomas are considered high-grade tumors by 
definition by the majority of authors [10]. 
The WHO (World Health Organization) and the International Society of Gynecological 
Pathology classification of tumours identifies seven histopathological types of endometrial 
carcinoma: 1) endometrioid carcinoma (adenocarcinoma; adenocarcinoma‐variants [with 
squamous differentiation; secretory variant; villoglandular variant; and ciliated cell variant) 
2) serous carcinoma, 3) clear cell carcinoma, 4) mixed carcinoma, 5) mucinous 
adenocarcinoma, 6) undifferentiated carcinoma, 7) carcinosarcoma, 8) neuroendocrine 
carcinomas, and 9) other unusual types [11]. 
These types differ as for precursor lesions, molecular features and natural history. 
Serous and clear cell carcinomas are considered as aggressive histologic types. Patients with 
these types of tumors are often diagnosed at advanced stage (FIGO III-IV in 33-41% of cases). 
Carcinoma of the endometrium comprises also mixed epithelial and mesenchymal 
tumors which include: adenomyoma, atypical polypoid adenomyoma, adenofibroma and 
adenosarcoma. These histotypes are not concerned in this introduction. 
Although the classification proposed by Bokhman in 1983 is frequently used in clinical 
decision-making, it has been observed that its prognostic value does not apply to all cases. It 
is estimated that 20% of endometrioid carcinomas will recur, while up to 50% of type 2 
carcinomas will never relapse. Consequently, it seems that endometrial carcinoma comprises 
a great variety of clinical entities where genetic factors and molecular characteristics could 




b) Molecular classification  
To overcome these problems The Cancer Genome Atlas Research Network (TCGA) 
performed integrated genomic, transcriptomic and proteomic characterization of 373 
endometrial cancer patients [12]. As a result of this work published in 2013 in Nature, a new 
molecular classification of endometrial cancer was proposed. Their results classified 
endometrial cancers into four categories: somatic inactivating mutations in polymerase Ɛ 
exonuclease (POLE ultramutated, 7%), microsatellite instability hypermutated (MSI 
hypermutated, 28%), copy-number low (non-specific molecular profile, 39%) and copy-
number high (serous-like, frequent TP53 mutations, 26%). Uterine serous carcinomas share 
genomic features with ovarian serous and basal-like breast carcinomas. These results gave 
evidence that the genomic features of endometrial carcinomas permit a reclassification that 
may affect surgical management, provide guidance for post-surgical adjuvant therapy and 
disease surveillance. 
The POLE ultramutated group is characterized by an excellent prognosis, whereas the 
TP53 mutated group typically indicates poor prognosis tumors. 
These findings were analyzed in a large randomized trial population (PORTEC group), 
which confirmed a prognostic capacity of these subgroups [13]. 
Following these studies, another group developed a simplified, pragmatic, molecular 
classifier, called Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE), which 
identifies four molecular analogues subtypes to the four genomic subtypes described in TCGA. 
Mismatch repair deficient (MMR-D), showing loss of one or more mismatch repair protein(s), 
corresponds to the MSI-H/hypermutated subtype. DNA polymerase epsilon (POLE), with 
mutations in the exonuclease domain in exons 9–14, corresponds to the ultramutated 
subtype. P53 abnormal (p53abn) demonstrating aberrant p53 immunohistochemical staining, 
corresponds to the copy number high subtype. Finally, p53 wild-type (p53wt) corresponds to 
the copy number low subtype [14, 15]. 
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In contrast to the TCGA methods that depend on fresh-frozen material and require 
costly and complex methodologies, ProMisE can be achieved on formalin-fixed, paraffin-
embedded material using methods easily adopted in pathology labs at most cancer centres. 
The usefulness of TCGA approach has been confirmed particularly in high-grade 
endometrioid carcinoma, and serous carcinoma. POLE mutated high-grade endometrioid 
carcinoma, have an excellent prognosis. P53 abnormal tumors are characterized by poor 
outcome. This is the situation of the majority of serous carcinomas (95%). Endometrioid 
carcinoma with MSI or NSMP, have an intermediate prognosis and they represent the vast 
majority of low-grade endometrioid carcinoma. 
In summary, TCGA molecular surrogate is particularly of interest in high-grade 
endometrioid carcinoma and tumors in the grey zone between endometrioid carcinoma and 
serous carcinoma. The decision to implement the molecular-based surrogate in all 
endometrial cancers, or just in high-grade tumors, or in any of them depends on the available 
resources. If molecular classification tools are not available, endometrial cancer 
characterization should be based on traditional pathological features. There is still room for 
other biomarkers that may be potentially useful in the big group of low-grade endometrioid 
carcinoma with NSMP, such as L1CAM expression or mutations in CTNNB1. However, in this 
group, appropriate pathologic staging and assessment of lymphovascular space involvement 
(LVSI), seems to be particularly useful. 
c) New biomarkers  
L1 cell adhesion molecule (L1CAM) was found to be a promising biomarker for 
identification of patients with poor outcome, which has been confirmed in subsequent 
studies. Other prognostic biomarkers in endometrial cancer are: markers of the p53 pathway, 
hormone receptor expression, and microsatellite instability [16, 17]. 
Pathological information has been used to estimate risk of nodal metastasis and define 
prognosis (recurrence, survival) in endometrial cancer. These prognostic factors are widely 




4. PREOPERATIVE ASSESMENT 
Preoperative evaluation of endometrial cancer using modern imaging methods is 
universally recommended before surgical treatment. The preoperative imaging issues to 
evaluate the extent of myometrial, cervical invasion and the presence of extrauterine disease. 
Magnetic resonance imaging (MRI) is the standard method used in preoperative 
assessment with highest interobserver concordance [18]. Transvaginal ultrasound is found to 
have similar sensibility and specificity in experienced hands [19]. In contrast, computerised 
tomography is not useful to assess the extent of uterine disease (myometrial or cervical 
invasion) but it can be used to determine extrauterine disease (regional metastatic lymph 
nodes or metastatic distant disease). The use of PET-CT in early stage endometrial cancer is 
questionable. Its utility and prognostic value is proven in advanced endometrial cancer [20]. 
The role of preoperative assessment is to establish a recurrence risk group, on basis of 
myometrial invasion and cervical involvement to predict the risk of lymph node metastasis 
and to plan a surgical strategy. 
5. STAGING CLASSIFICATIONS 
Multiple risk models have been created on the basis of pathologic information to 
define prognosis and estimate risk of nodal metastasis in endometrial cancer. FIGO 2009 and 
TNM classifications are the most widely used (Table II, III) [21, 22]. They are based on presence 
or absence of local or metastatic disease based on surgical staging. FIGO/TNM classifications 
include the assessment of the extent of myometrial invasion. Deep endometrial invasion is an 
additional factor predictive of nodal involvement and survival. In the GOG trial published in 
1991, authors found 94% 5-year survival when the tumor was confined to endometrium, 91%, 
84% and 56 % when the myometrium was invaded <33%, 33-66% and >66%, respectively [23]. 
FIGO stage is one of the strongest predictors of outcome in patients with endometrial 
cancer. For example, patients with nodal metastases in endometrial cancer have poorer 
prognosis when compared with negative nodes patients. FIGO publication showed 57% 5-year 
survival in patients with stage IIIC disease when compared to 74-91% in patients without 




FIGO Stage  
I Tumor confined to the corpus uteri 
IA No or less than half myometrial invasion 
IB Invasion equal to or more than half of the myometrium 
II Tumor invades cervical stroma, but does not extend beyond the uterus (A) 
III Local and/or regional spread of the tumor 
IIIA Tumor invades the serosa of the corpus uteri and/or adnexae (B) 
IIIB Vaginal involvement and/or parametrial involvement 
IIIC Metastases to pelvic and/or para‐aortic lymph nodes 
IIIC1 Positive pelvic nodes 
IIIC2 Positive para‐aortic nodes with or without positive pelvic lymph nodes 
IV Tumor invades bladder and/or bowel mucosa, and/or distant metastases 
IVA Tumor invasion of bladder and/or bowel mucosa 
IVB Distant metastasis, including intra‐abdominal metastases and/or inguinal 
nodes) 
 
Table II. Current FIGO 2009 staging classification for cancer of the corpus uteri [21]. 
A: Endocervical glandular involvement only should be considered as Stage I and no longer as Stage II. 






FIGO Stage Union for International Cancer Control (UICC) 
T (tumor) N (lymph nodes) M (metastasis) 
I T1 N0 M0 
IA T1a N0 M0 
IB T1b N0 M0 
II T2 N0 M0 
III T3 N0–N1 M0 
IIIA T3a N0 M0 
IIIB T3b N0 M0 
IIIC1 T1–T3 N1 M0 
IIIC2 T1–T3 N1 M0 
IVA T4 Any N M0 
IVB Any T Any N M1 
 
Table III. Cancer of the corpus uteri: FIGO staging compared with the TNM classification [22]. 
 
Different risk models have been created to adjust more accurately the risk 
stratification systems. These classifications add other prognostic factors not included in 
FIGO/TNM classification such as age, grade and type of tumor, tumor size and the presence of 
LVSI. 
The European Society of Medical Oncology (ESMO) [24] and more recently together 
with the European Society of Gynecologic Oncology (ESGO) and the European Society of 
Radiation Oncology (ESTRO), a risk classification system has been published (Table IV, V), 
which is the one most commonly used in Europe to tailor adjuvant treatment and also to plan 




Risk group Description 
Low Stage I endometrioid, grade 1 or 2, <50% myometrial invasion, LVSI negative 
Intermediate Stage I endometrioid, grade 1 or 2, ≥ 50% myometrial invasion, LVSI negative 
High-
intermediate 
Stage I endometrioid, grade 3, <50% myometrial invasion, regardless of LVSI 
status 
Stage I endometrioid, grade 1 or 2, LVSI unequivocally positive, regardless of 
depth of invasion 
High Stage I endometrioid, grade 3, ≥50% myometrial invasion, regardless of LVSI 
status 
Stage II 
Stage III endometrioid, no residual disease 
Non endometrioid (serous or clear cell or undifferentiated carcinoma or 
carcinosarcoma) 
Advanced Stage III residual disease and stage IVA 
Metastatic Metastatic Stage IVB  
 
Table IV. Risk groups according to ESGO/ESMO/ESTRO 2016 classification [25]. 
 
Risk group Description 
Low Stage I endometrioid, grade 1 or 2, <50% myometrial invasion 
Intermediate Stage I endometrioid, grade 1 or 2, ≥ 50% myometrial invasion 
Stage I endometrioid, grade 3, <50% myometrial invasion 
High Stage I endometrioid, grade 3, ≥50% myometrial invasion 
Non endometrioid (serous or clear cell or undifferentiated carcinoma or 
carcinosarcoma) 
Table V. Risk groups according to ESGO 2010 classification [24]. 
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6. DEFINITIONS OF INTERMEDIATE RISK ENDOMETRIAL CANCER  
a) Intermediate risk classifications based on traditional pathological features 
When looking back into literature, the risk classifications have substantially changed in 
the last 20 years. Regrettably, the definition of intermediate risk and high-intermediate risk 
endometrial cancer is not universal. These differences in definition make it difficult to 
extrapolate the results of studies addressing the prognosis of intermediate low and high risk 
endometrial cancer patients. For example, in GOG 99 high-intermediate risk patients were 
defined as: 1) moderate to poorly differentiated tumors, presence of LVSI and outer third 
myometrial invasion; 2) age 50 or greater with any two risk factors listed above; or 3) age of 
at least 70 with any risk factor listed above. Intermediate low-risk was defined as age ≤50 and 
≤2 risk factors; age 50-69 and ≤1 risk factor or age ≥70 years without risk factors [26]. In 
contrast, The PORTEC-1 definition of high-intermediate risk is two of the following three 
factors: age >60, more than one half myometrial invasion, and grade 3 disease. Intermediate 
low was defined as 1) stage I, grade 1, myometrial invasion ≥50%; 2) stage I, grade 2 or 3) stage 
I, grade 3, myometrial invasion <50%. The latter definition was further used in ESMO 2010 for 
the definition of intermediate risk [24, 27]. An interesting review both on PORTEC 1 and GOG 
99 classification of high/intermediate risk patients showed that adjuvant radiation was 
associated with an overall survival benefit in patients meeting GOG-99 criteria only; however, 
no survival benefit was seen in patients meeting PORTEC-1 criteria only. The authors proposed 
a new classification on these findings [28]. 
One study compared the accuracy of different risk stratification, demonstrating that 
none of the five major risk systems shows high accuracy to stratify recurrence risk and nodal 
metastases in early-stage endometrial cancer [29]. 
Different international societies add different criteria to consider high-intermediate 
risk patients and need for adjuvant brachytherapy. The National Comprehensive Cancer 
Network (NCCN) includes extensive LVSI, age, tumor size and lower uterine segment invasion 
as additional risk factors [30]. The new NCCN criteria classified patients as high-intermediate 
group based on GOG 249 study. High intermediate group is defined as: age 50-69 years with 
two risk factors or <50 years with 3 risk factors. The American Society for Therapeutic 
Radiation Oncology guidelines specify age >60 and LVSI as adverse risk factors [31]. 
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b) Molecular classification 
New NCCN guidelines mention the molecular classification in recommendations. 
According to these guidelines, molecular testing is counselled to all endometrial cancer 
patients, especially in patients with high-grade endometrioid cancer. Schematic proposition 
of implementation of molecular testing after Murali et al., is presented in the Figure 3 [32]. 
 
Figure 3. Diagnostic algorithm for integrated genomic-pathologic classification of endometrial carcinomas 
(blue=histotype; red=TCGA genomic class) [32]. 
MSI-H: microsatellite instability high; *May also apply to clear cell carcinomas; **This algorithm does not 
distinguish between histotypes of TP53-mutated copy-number-high tumors, i.e., high-grade endometrioid 
carcinoma, serous carcinoma, or clear cell carcinoma 
 
Holding all the new molecular local predicting factors markers that could potentially 
permit to classify patients into risk groups, the question of interest of lymph node dissection 
may again be put forward. 
However, for the moment it is uncertain whether preoperative ProMisE/TCGA 
classification (using biopsy or curettage specimen) can be used to select patients to different 
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types of staging surgery. For example, patients with POLE-mutant tumors might not need 
comprehensive surgical staging. Similarly, patients with serous and serous-like carcinomas 
may not benefit from comprehensive surgical staging, since nearly all will require adjuvant 
chemotherapy and it is possible that full surgical staging may only be applicable to the 
remaining categories. 
None of the international societies considers the TCGA biomarkers in prognostic risk 
group stratification to guide adjuvant treatment so far. This is probably due to lack of 
prospective data that would support the real benefit of this classification. 
c) ESGO/ESMO/ESTRO 2016 CLASIFICATION 
In 2016 a joint consensus of European Societies (ESGO, ESMO and ESTRO) has decided 
to change the risk stratification system. The subclassification of intermediate risk endometrial 
cancer was introduced and a new definition of high-intermediate group was added. High-
intermediate risk was described as: 1) stage I endometrial, grade 3, myometrial invasion <50%, 
independently of LVSI or 2) stage I endometrial grade 1-2, LVSI invasion unequivocally positive, 
independently of myometrial invasion [25]. This new subclassification into standard 
intermediate and high-intermediate risk was supported by retrospective reports, which 
documented adverse prognosis of LVSI positive and grade 3 tumors. LVSI with an emphasis on 
‘extensive’ was incorporated as an important prognostic factor [33-37]. The presence of 
extensive LVSI classifies patients into high-intermediate risk group. 
The introduction of extensive LVSI in the risk stratification has been an important point, 
as this histologic feature strongly impacts prognosis in early stage endometrial cancer and 
should be precisely reported in the pathological report. Research based on PORTEC 1 and 2 
cases highlighted the importance of quantifying the number of vessels involved with LVSI as 
focal or substantial/extensive. Substantial LVSI, in contrast to focal or no LVSI, was found to 
be the strongest independent prognostic factor for pelvic regional recurrence, distant 
metastasis and overall survival [38]. Examples of focal and extensive LVSI are represented in 




Figure 4 A, B. A: focal lymphovascular space invasion (LVSI). B: Representative examples of substantial LVSI. Black 
boxes indicate foci of LVSI. (Bosse et al. [38]). 
7. SURGICAL MANAGEMENT OF INTERMEDIATE AND HIGH-INTERMEDIATE ENDOMETRIAL CANCER 
As a transitional risk group between low and high risk endometrial cancer, the 
management of intermediate risk endometrial cancer patients is frequently an issue of 
controversy. The debate is frequently focused on the indication of lymph node dissection and 
adjuvant treatment. 
There is a universal consensus that total hysterectomy with bilateral salpingo-
oophorectomy is the standard treatment for apparent stage I endometrial cancer and is 
effective in most cases [25]. 
The majority of international guidelines already agree that patients classified as ESMO 
low risk tumors (FIGO IA, grade 1 and 2 without LVSI) for recurrence could benefit from the 
conservative staging procedures without lymph node dissection and no adjuvant treatment is 
recommended [1, 25]. 
On the contrary, in high risk endometrial cancer (Stage IB grade 3 endometrioid type 
with positive LVSI or non-endometrioid disease of all stages) comprehensive surgical staging 
including hysterectomy with bilateral salpingo-oophorectomy, pelvic washing, and pelvic and 
para-aortic lymph node dissection is recommended. 
This opinion is based on prognostic significance of lymph nodes involvement known 
from decades and has given the idea of full lymph node staging in order to improve survival. 
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However, there is only one retrospective study that evidenced a survival improvement of 
complete surgical staging [39, 40]. However, non-randomized studies support these data [41, 
42]. 
Our group has published a matched pair retrospective multicenter study and has 
observed the lack of prognostic value of lymphadenectomy in high risk endometrial cancer 
[43]. 
8. ADJUVANT TREATMENT IN INTERMEDIATE AND HIGH-INTERMEDIATE ENDOMETRIAL CANCER 
The therapeutic role and the modalities of adjuvant treatment in endometrial cancer are 
also controversial. The publication of the Dutch PORTEC group trial has resulted in reduction 
of adjuvant radiotherapy in early stage endometrial cancer. The PORTEC 1 study showed no 
benefit in overall survival for patients with low or intermediate risk endometrial cancer, 
whether they received adjuvant radiation therapy or not [27]. PORTEC 2 study compared 
vaginal brachytherapy versus external beam radiotherapy for patients with high-intermediate 
risk endometrial cancer (PORTEC risk stratification) and found no differences in disease-free 
survival. Toxicity and quality-of-life profile were more favourable in the brachytherapy arm 
[44]. 
The results of these trials have been universally implemented. In consequence, in 85% of 
patients with early stage endometrial cancer routine adjuvant radiotherapy has been 
abandoned. Of note, lymphadenectomy was not done routinely in the PORTEC trials. The 
authors of PORTEC 1 suggest that these results should not motivate surgeons to perform more 
lymph node dissections in order to find microscopic disease, as this increases morbidity 
without benefit on overall survival [45]. 
The ASTEC/EN.5 trial has analysed intermediate or high risk of recurrence patients, 
randomised to either adjuvant brachytherapy and external beam radiotherapy (EBRT) or 
brachytherapy alone. Only 31% and 28% of patients in each group, respectively, underwent 
lymphadenectomy (pelvic or pelvic and para-aortic). This study has shown no evidence of 
benefit for external beam radiotherapy for early endometrial cancer in terms of overall, 
disease-specific, and disease-specific recurrence-free survival [46]. 
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Finally, the GOG 99 trial studied specifically intermediate risk endometrial carcinoma. The 
authors concluded that adjuvant EBRT decreases the risk of recurrence, but should be limited 
to high-intermediate risk patients. In absolute terms, EBRT patients in the group of high-
intermediate risk resulted in a 19% improvement in cumulative incidence of recurrence at 24 
months when compared to the control group. Overall survival seemed to be better in the 
radiotherapy arm (92% versus 86%, respectively). However, it did not reach statistical 
significance. Of note more than 50% of the deaths reported in GOG 99 were not cancer related 
[26]. 
A meta-analysis on the effect of external beam radiotherapy on overall survival in 
intermediate risk and high risk early-stage disease, including Cochrane and ASTEC/EN.5 
results, showed a non-significant hazard ratio of 1.04 (95% confidence interval 0.84–1.29; 
p=0.38) [46]. Based on this finding, the European consensus panel recommends external beam 
radiotherapy only in the subgroup of high-intermediate risk patients with unknown nodal 
status [25]. 
This leads to another challenging discussion on endometrial cancer adjuvant 
treatment. If 5-year overall survival rates range around 90% and the disease affects elderly 
patients, it is extremely difficult to prove that any treatment will improve the overall survival. 
Still importance on DFS improvement with radiotherapy is not negligible as it may improve 
the quality of life. This is documented in patient’s preference study that showed patient choice 
towards a treatment to prevent the relapses [47]. 
According to European guidelines and based on strong evidence supported by the 
results of PORTEC group trials patients with low risk endometrial cancer features are not 
candidates for adjuvant radiation therapy. These patients managed with surgery only have 
95% probability of relapse-free survival at 5 years. 
EBRT is still indicated for patients characterized as high risk of recurrence. 
For intermediate risk endometrial cancer adjuvant brachytherapy is currently a 
standard treatment. This therapy is recommended to decrease vaginal recurrence. No 
adjuvant treatment is an option, especially for patients aged <60 years. 
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Randomized clinical trials have shown very good vaginal control with adjuvant 
brachytherapy, and only 2% vaginal recurrence. Overall survival rates are comparable to EBRT 
arm in intermediate risk endometrial cancer patients. These results were confirmed in the 10-
year analysis of the PORTEC-1 trial [45]. 
A Danish gynecologic oncology group presented a nationwide prospective study and 
demonstrated that postoperative radiotherapy could be omitted in low and intermediate risk 
stage I patients without loss of survival. For this reason, European guidelines mention an 
omission of treatment as an option, especially for patients younger than 60 years [48]. 
In the 10-year analysis of PORTEC 2 trial, it has been shown that patients that 
presented with substantial LVSI, p53abn or L1-CAM overexpression had a hardly higher risk of 
pelvic relapse with brachytherapy than those who were managed with EBRT [49]. 
In high-intermediate group, European guidelines recommend external-beam 
radiotherapy for patients with unknown lymph node status. 
NCCN guidelines recommend vaginal brachytherapy as a preferred option for 
intermediate risk endometrial cancer, or observation, if no other adverse risk factors are 
present (age > 60, LVSI). In case of high-intermediate risk vaginal brachytherapy is still 
preferred, however, external beam radiotherapy can be considered [30]. 
9. CONTROVERSIES ON SURGICAL STAGING: THE ISSUE OF LYMPH NODE DISECTION 
The role of staging procedure in any malignant tumor is to define similar patients’ 
populations referring to prognosis and therapy. In endometrial cancer, surgical staging has 
been introduced in 1988 after the publication of the Gynecologic Oncology Group (GOG) study 
[50]. That year, the International Federation of Gynecology and Obstetrics (FIGO) and GOG 
recommended systematic surgical procedure that included hysterectomy with bilateral 
oophorectomy (TH&BSO), pelvic washing, and pelvic and para-aortic lymph node dissection 
(LND) in patients who presented risk factors including unfavorable histology and myometrial 
invasion. However, systematic LND has been lately a reason of debate. The doubts are more 
than justified considering the generally underestimated, serious consequences and possible 




a) Tumor characteristics predictive of nodal involvement 
Pathological information has been used to estimate risk of nodal metastasis and define 
prognosis (recurrence, survival) in endometrial cancer. These prognostic factors are widely 
used to classify patients into risk groups to guide surgical management and adjuvant 
treatment. 
The grade of histologic differentiation is a known factor of tumor spread. It is directly 
related to myometrial invasion, risk of nodal involvement and in consequence overall survival. 
The relative risk of death for patients with grade 3 compared to grade 1 in PORTEC trial was 
4.9 vs. 0.45, respectively [27]. 
Deep endometrial invasion is an additional factor predictive of nodal involvement and 
survival. In the GOG trial published in 1991, authors found 94% 5-year survival when the tumor 
was confined to endometrium, 91%, 84% and 56 % when the myometrium was invaded <33%, 
33-66% and >66% respectively [23]. 
LVSI is defined as the presence of viable tumour cells within endothelium-lined spaces, 
typically as clusters of cells that appear “free-floating” and often conform to the shape of the 
space. It is found in around 10-15% of FIGO stage I endometrial cancers. The presence of LVSI 
is a well-known prognostic factor in endometrial cancer and should always be recorded in the 
pathology report. A recently published novel LVSI classification based on PORTEC 1 trial points 
out the importance to quantify the number of vessels involved with LVSI as focal or 
substantial/extensive. According to the authors substantial LVSI, in contrast to focal or no LVSI, 
was the strongest independent prognostic factor for pelvic regional recurrence, distant 
metastasis and overall survival [38]. The reproducibility of this new LVSI classification has been 
validated in an ancillary study by Peters et al. [51]. 
Involvement of more myometrial vessels and more distant vessels is closely related to 
the probability of lymph node metastasis and a shorter disease-free and overall survival [52]. 
LVSI confined to rare vessels are of questionable prognostic value and classified by 
some pathologists as “indeterminate,” corresponding to the definition of “focal”. 
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The pseudo LVSI artifacts mimicking LVSI has also been found due to processing or 
uterine manipulation during laparoscopic surgery. Although the differential diagnosis is 
sometimes extremely difficult the effort should be made to distinguish true LVSI from such 
mimics, since the pseudo LVSI is not a prognostic factor [53]. 
Finally, LVSI as an important prognostic factor, with an emphasis on ‘extensive’ has 
been added to the ESGO/ESMO/ESTRO risk stratification. The presence of extensive LVSI, 
classifies patients into high-intermediate risk group. 
While conventional pathology remains the standard for the diagnosis of endometrial 
cancer, its main problem is the inter-observational reproducibility. Various studies have 
shown that a high-grade endometrial cancer diagnosis is not highly reproducible. Some 
pathologists have observed even 10% of discordance in pathological diagnosis in high-grade 
endometrial tumors [54, 55].  
Another issue is the limitation of prognostic value of standard pathology. Interestingly, 
not all high-grade tumors relapse and not all low-grade tumors show good prognosis. 
b) Risk and complications related to lymph node dissection. 
Potential risks of lymph node dissection must be taken into account in the risk/benefit 
balance. 
Intraoperative and postoperative morbidity has been described in around 8% of para-
aortic lymph node dissections (LND) [41, 56]. 
The most common intraoperative complications are vascular injuries, occurring up to 
5% of cases. These can lead to conversion to laparotomy when major vessels are involved. 
Acute arterial dissection is a rare serious vascular complication described in the literature [57]. 
Deep venous thrombosis and/or pulmonary embolism have been reported in approximately 
0-8% in modern series. Lymphocele is directly associated with an increased risk of 
thromboembolic events. 
Ureteral and bowel injuries are infrequent complications that have also been reported 
in lymphadenectomy. Severe nerve injuries are rarely reported in the literature. The most 
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frequent neuronal complication concerns the obturator nerve. In this case, usually we speak 
about a nerve contusion or so called neuropraxia. Recovery is expected to occur within 6 
weeks. In more severe cases the functional recovery occurs within 6-12 month. The injury of 
obturator nerve can be a cause of pain, sensory loss to the medial thigh and inconstant loss of 
adductor muscle function. Long-term motor consequences, even if complete division occurs, 
are extremely rare. This is due to dual innervation of several adductors’ muscles and presence 
of an accessory obturator nerve [58]. 
Long-term complications associated to LND are mainly lymphocele and lower limb 
lymphedema. The exact incidence of these complications is unknown and usually 
underestimated. Lymphoceles are lymph-filled collections without a distinct epithelial lining, 
caused by the disruption of efferent lymphatics during LND. The incidence of lymphocele 
formation ranges from 1 to 58%. Most lymphoceles are asymptomatic and resolve 
spontaneously with the development of new lymphatic vessels. Symptomatic lymphoceles are 
described in 5-34.5% of cases. Signs are habitually related to compression to adjacent organs, 
infection, or discharge related to spontaneous drainage [59-61]. Lymphedema is defined as a 
chronic, dynamic condition in which protein rich fluid accumulates in the superficial tissues. It 
occurs in 12% up to 40% of patients surgically staged for endometrial cancer. This difficult 
condition may cause discomfort, heaviness but also reduced mobility in these patients. It is 
related to reductions in both physical and mental quality of life 3-5 years after cancer 
treatment [62-66]. 
Adjuvant radiotherapy, extensive nodal dissection (higher node count), and removal of 
circumflex iliac nodes to the distal external iliac nodes, are described as the main risk factors 
of lymphedema [67]. 
A recently published large prospective trial (GOG 244) assessed the incidence of 
lymphedema by regular measuring of the leg volume with a follow up of 48 months. The 
authors observed lymphedema defined by volume change >10% - in 34% of endometrial 
cancer patients fully staged with pelvic and para-aortic LND. Advanced age and node count 
over 8, were found as the main risk factors. Increase risk of lymphedema was not associated 
with radiation, advanced stage or other commonly reported risk factors [68]. 
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Other authors use the Lymphedema PRO e-mail surveys. This is the case of Leitao et 
al. study [69] that compared the prevalence of patient-reported lower-extremity lymphedema 
in patients with newly diagnosed endometrial carcinoma who underwent full surgical staging 
(para-aortic and pelvic lymphadenectomy) when compared with sentinel lymph node biopsy. 
The authors observed a prevalence of lymphedema in order of 41% in the lymphadenectomy 
group compared to 27% in the sentinel lymph node group that surprisingly is comparable to 
the group without any lymph node mapping. It suggests that the incidence of this complication 
is probably overestimated in this article. Authors concluded that sentinel lymph node mapping 
over lymphadenectomy is independently associated with a significantly lower prevalence of 
patient-reported lower-limb lymphedema. 
The results were confirmed in a prospective multicentric trial publication on cervical 
cancer–SENTICOL 2 presented at SGO meeting in 2017, yet unpublished [70]. 
c) Therapeutic value of lymphadenectomy 
THE POTENTIAL OF SURGICAL RESECTION OF NODAL DISEASE 
Some historical publications pointed out the therapeutic value of surgical excision of 
positive lymph nodes. These data have not been confirmed in previously mentioned 
prospective trials [41, 42]. However, a few retrospective works suggested that full lymph node 
dissection have a positive impact on patient’s survival. The question remains tough 
controversial. A control case study published in 1996 suggested that patients who underwent 
pelvic node sampling had better outcome [71]. Different publication showed improved 
prognosis in patients with positive lymph nodes or with high-grade tumors [72, 73]. 
The SEPAL study showed also better outcome in patients undergoing pelvic and para- 
aortic lymphadenectomy versus pelvic lymphadenectomy only. However, also in this 
retrospective study adjuvant therapy was not comparable in the two groups. In patients who 
underwent both pelvic and para‐aortic lymphadenectomy, 77% received chemotherapy and 
only 45% in the pelvic lymphadenectomy group [74]. 
Therefore, for the moment, there is no definitive evidence that lymphadenectomy has 
a therapeutic value. According to the available evidence its role is mainly prognostic and 
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serves as information to guide further adjuvant treatment. Consequently, if the same 
prognostic information can be obtained by SLN biopsy alone, the patient could be spared the 
risks associated with comprehensive LND. 
THE ROLE OF LYMPH NODE DISSECTION IN TAILORING ADJUVANT TREATMENT 
The information provided by the lymph nodal assessment is traditional a major 
argument in favour of adjuvant treatment. Lymph node involvement has been the most 
important prognostic information in patients with endometrial cancer. However, this 
paradigm has recently lost in importance. 
The authors of PORTEC-1 trial suggest that 9% prevalence of microscopic lymph nodes 
disease in early stage endometrial cancer patients probably do not justify the morbidity of 
systematic lymph node dissection. In none of the previously mentioned randomised studies 
on radiotherapy in endometrial cancer, lymph node status has been taken into account. 
Even if the decision on radiotherapy is a minor question facing the results of PORTEC, 
ASTEC/EN.5 and GOG 99 trials, still the decision on adjuvant chemotherapy could be 
influenced by the nodal status and impact survival. Positive lymph node is still standing 
indication for adjuvant therapy. These recommendations are supported by the PORTEC 3 trial, 
and the recently published GOG 258 trial [75, 76]. 
PORTEC 3 trial randomized patients with high‐risk Stage I–II (32% grade 3 and 29% 
serous or clear cell cancer) or with Stage III (45%) endometrial cancer to either pelvic EBRT 
alone or EBRT with two concurrent cycles of cisplatin in weeks 1 and 4 of EBRT, followed by 
four cycles of carboplatin and paclitaxel. In this study women with Stage III disease had the 
highest absolute benefit of chemoradiotherapy, with 5‐year failure‐free survival of 69% versus 
58% for radiotherapy alone (P=0.03) [75]. 
In the randomized GOG‐258 trial for Stage III and Stage IV (residual disease <2 cm 
allowed), 813 patients were randomized to receive either chemoradiotherapy as used in 
PORTEC‐3 or six cycles of carboplatin and paclitaxel without radiotherapy. This last study 
showed non-inferior DFS and OS in patients FIGO stage III and IV that received only adjuvant 
chemotherapy [76]. Results of GOG 258 and PORTEC 3 again pose a challenge in the discussion 
about the relevance of lymph node dissection. According to current guidelines, for patients 
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with Stage III endometrial cancer, the combination of adjuvant chemotherapy and EBRT seems 
most effective to increase the DFS. 
Despite of this evidence there is no proof that the abstention of adjuvant treatment in 
patients with positive lymph nodes has a negative impact on survival. As for our knowledge 
and after a thorough bibliographic research there is no trial that compared adjuvant treatment 
versus no treatment in patients with lymph node disease. In other words, knowledge of the 
presence or absence of lymph node metastasis may change treatment approaches and 
indicate different management, but the impact of those changes on overall survival is not clear 
at all. However, the fact is that if combined treatment -radiation therapy with chemotherapy 
- is more effective than radiation therapy in stage IIIC endometrial cancer patients (as revealed 
in the PORTEC 3 trial), this fact would appeal for a therapeutic effect of chemotherapy. The 
evidence is even stronger with the results of GOG 258 trial. These results speak in favour for 
lymph node dissection in groups with high risk of lymph node involvement. 
Going further in the discussion, the decision about adjuvant treatment could 
theoretically be guided only on the basis of local pathological risk factors (grade, type, LVSI), 
independently of nodal status. Actually, it is unknown if adjuvant therapies given to lymph 
node positive or patients with unknown node status perform similarly. 
This is probably even more valid if molecular prognostic factors are used in 
complement of the traditional pathologic characteristics. The potential of biomarkers in 
tailoring adjuvant therapy was suggested already in two promising papers [16, 77] and is being 
investigated in the PORTEC 4a trial. [78]. This prospective phase III trial investigates the role 
of an integrated clinicopathological and molecular risk profile to determine if patients with 
high-intermediate risk features should receive no adjuvant therapy, vaginal brachytherapy or 
external beam radiotherapy. Awaiting the results of this study, the current 
ESGO/ESMO/ESTRO subclassification of intermediate risk has to be taken into account for 
adjuvant treatment planning. The same will remain valid in the future in settings where 
molecular biology resources are not available. 
Taking into consideration the difficulty in assessing LVSI preoperatively and the 
controversy regarding full lymph node dissection, the current development of the SLN 
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technique is likely to be the best staging compromise in intermediate risk cancer patients 
[79] (see below). 
d) Evidenced based lymphadenectomy (prospective/retrospective) 
There are two prospective randomized studies analyzing the role of LND in endometrial 
cancer [41, 42]. Both Benedetti Panici group and ASTEC study concluded that apparently there 
is no survival benefit of LND neither in low risk nor intermediate/high risk endometrial cancer. 
Both studies recruited a large number of patients, and investigators observed a large 
number of events to establish the survival outcome. However, both studies were widely 
criticized. The main drawback of the ASTEC study was the absence of routine para-aortic LND 
in the lymphadenectomy group, the low mean number of nodes retrieved when LND was 
performed and the mathematical model used in the analysis. Another major criticism was the 
high proportion of low‐risk patients that might have biased the results. In the Benedetti Panici 
trial, which randomized only intermediate and high risk patients, para-aortic LND was 
performed only in a small (26%) proportion of patients from LND group. This trial, showed no 
statistically significant differences for vaginal recurrence (2.6% for LND group vs. 2.4% for no 
LND group), lymph node recurrence (1.5% vs. 1.6%), and intraperitoneal relapse (3% vs. 2.8%) 
between the two arms of the study. 
A secondary analysis of this randomized study was further performed. The authors 
found a poorer prognosis in obese and elderly patients whether or not they underwent 
lymphadenectomy and irrespective of the presence of nodal metastasis [80]. 
The survival results of these prospective trials were combined in a Cochrane group 
meta-analysis [81]. The conclusion of this review indicated no significant differences in overall 
and recurrence-free survival between women who underwent lymphadenectomy and those 
who did not undergo lymphadenectomy. In this meta-analysis the hazard ratio was 1.07 (95% 
confidence interval 0.81 to 1.43) for overall survival and hazard ratio 1.23 for recurrence-free 
survival (95% Confidence Interval 0.96 to 1.58). 
The evidence from these randomized clinical trials did not show a clear benefit of LND 
for women with early-stage endometrial cancer. The authors of the Cochrane meta-analysis 
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suggested that it is questionable whether additional trials in this area are justified. However, 
the authors of this analysis evoked the need of studies for intermediate risk patients 
independently. 
Indeed, a new clinical trial was opened to recruitment 2 years ago and is ongoing. The 
Endometrial Cancer Lymphadenectomy Trial (ECLAT), (NCT03438474) aims to assess whether 
or not systematic pelvic and para-aortic LND have a significant impact on overall survival in 
patients with high risk endometrial cancer. The results of this trial are expected by the end of 
2029 [82]. 
LND in intermediate/high risk endometrial cancer has been also studied in numerous 
retrospective trials, showing controversial results in relation to its survival benefit [83, 84]. 
Similarly, differences between pelvic and para-aortic LND compared to pelvic LND 
alone have been studied, again with controversial results [85, 86]. The SEPAL study concluded 
that comprehensive para-aortic LND had survival benefits (DFS and OS) for patients with 
intermediate and high risk endometrial cancer compared to pelvic LND alone. The median 
lymph node count was 34 in pelvic LND group and 82 on pelvic and para-aortic group. FIGO 
stage IIIC disease was found in 16% of patients. The considerable node count could speak in 
favor of therapeutic role of LND. However, the outcome of no-LND group was not reported, 
which makes a definitive conclusion impossible. Another recently published retrospective 
study concluded that the combination of pelvic/para-aortic lymphadenectomy significantly 
reduces the mortality in patients with intermediate risk compared to the patients who 
underwent no lymphadenectomy (hazard ratio 0.50, 95% confidence interval 0.43-0.81, 
p<0.0001) [74]. 
Another large multicentric retrospective study that included 27,063 patients with early 
stage endometrial cancer compared the outcome of women with or without 
lymphadenectomy. The authors concluded that lymphadenectomy is associated with an 
improved survival in stage I grade 3 and more advanced endometrioid uterine cancers [87].  
In contrast, the multicentric retrospective study published by Coronado et al. did not 
find any benefit for survival in intermediate risk endometrial cancer [88]. The results were 
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though limited by a low number of nodes removed, a low number of positive nodes and the 
absence of systematic para-aortic dissection. 
A similar multicentric study from the French FRANCOGYN Research Group was recently 
published, confirming those results [89]. 
e) Anatomical and pathological basis of LND in endometrial cancer 
The anatomy of lymphatic drainage of the uterus has been explored by Burke in his 
pivotal study on sentinel lymph node in endometrial cancer. In this study, the authors found 
bilateral lymphatic channels in the infundibulo-pelvic and broad ligaments. Interestingly, the 
authors did not identify para-aortic blue nodes below the level of the inferior mesenteric 
artery. This would suggest that the para-aortic lymphatic channels from the uterus go parallel 
to the ovarian vessels. The authors found also a great variation of the localization of pelvic 
nodes that would suggest heterogeneity of lymphatic routes [90]. 
Until the date we know that there are two pelvic lymph node spread pathways in 
endometrial carcinoma. The major route of drainage passes ventrally to the uterine vessels 
and internal iliac artery before entering the nodes in the proximal obturator fossa (at the 
bifurcation common iliac vessels) or on the medial surface of the external iliac vein. The other 
turns cephalad, rather than laterally in the parametrium, and enters the presacral nodes. The 
presence of this second drainage is not constant. Some authors named the two routes as 
upper and lower paracervical pathway, where the lower pelvic pathway drains to the SLN on 
the sacral promontory [91]. 
f) The role of para-aortic lymphadenectomy. 
Following the anatomical condition of lymphatic pathways, para-aortic 
lymphadenectomy should be performed up to the level of left renal vein. Thirty-five % of 
isolated aortic metastases are described to be located in the supramesenteric area [92]. The 
same study observed that 77% of patients in this group with any para-aortic node involvement 
had metastases above the inferior mesenteric artery. According to the pivotal study published 
in 1988 by Creasman, the overall probability of finding an isolated positive para-aortic lymph 
node is approximately 2% in apparently early stages of endometrial cancer with no pelvic 
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nodal disease. However, when it comes to high risk patients (type 2, grade 3; myometrial 
invasion >50%; primary tumor diameter >2 cm), the incidence of isolated positive para-aortic 
nodes was 16% [50, 92]. The same study observed that 77% of patients in this group with any 
para-aortic node involvement had metastases above the inferior mesenteric artery. 
When lymph nodes are found positive, the para-aortic nodes are involved in 50% of 
cases [93-95]. 
Recently published retrospective evidence is quite confusing. Some authors clearly 
state that para-aortic LND up to the level of left renal vein should always be performed in 
intermediate high risk patients, with a yield of 16% patients with para-aortic metastasis [92]. 
Other authors suggested to skip this procedure in the absence of pelvic node metastasis and 
deep myometrial invasion [96]. 
Better outcome of patients undergoing para-aortic LND was found in some 
retrospective trials maybe due to selection bias of patients. Those without important 
comorbidities would more often be subjected to the full staging procedure [97]. 
Therefore, probably only high risk patient might benefit from para-aortic lymph node 
dissection. Some authors consider only the combination of 2 risk factors (grade 3; myometrial 
invasion >50%; primary tumour diameter >2 cm) to indicate performing the para-aortic lymph 
node dissection. 
After the publication of the GOG 258 study in June 2019 not only the role of radiation 
therapy has been brought into question [76]. This clinical trial assessed whether 6 months of 
platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with 
longer relapse-free survival (primary end point) than six cycles of combination chemotherapy 
alone in patients with stage III or IVA endometrial carcinoma Secondary end points included 
overall survival, acute and chronic toxic effects, and quality of life. The results of the trial 
revealed that the chemotherapy with external beam radiation was not better than 
chemotherapy alone with respect to, disease free survival and overall survival. 
Interestingly this study questions as well the role of para-aortic lymphadenectomy in 
the treatment of apparently early stage endometrial cancer.  
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Anyway, in the era of sentinel lymph node, the discussion may be obsolete. Risk of 
complications associated with comprehensive lymph node dissection should not be neglected. 
g) Controversy on intermediate risk surgical management 
The most important controversy remains for tumors preoperatively classified as ESMO 
(ESGO/ESMO/ESTRO) intermediate risk for recurrence. The benefit in DFS and OS of 
lymphadenectomy in intermediate risk endometrial cancer is not clear and there is no 
consensus among international scientific societies. Our group has analyzed the impact of 
lymph node dissection in this group of patients in a match pair study without founding any 
benefit for survival in these types of tumors [88]. The NCCN panel recommends that 
lymphadenectomy should be done only in selected patients with endometrial cancer with 
para-aortic done as indicated for high risk patients [30]. The American College of Obstetrics 
and Gynecology still recommends comprehensive surgical staging as an initial management 
intermediate risk endometrial cancer [98], whereas others institutions suggest an individually 
adjusted LND approach [99]. 
The French guidelines highlight that there is no convincing data in the literature 
specifically for the intermediate risk patients. However, they propose the use of sentinel 
lymph node (SLN), awaiting the results of the national SENTIRAD study [100]. The European 
consensus of the three societies of Radiotherapy and Oncology (ESTRO), Gynecological 
Oncology (ESGO), and European Society of Medical Oncology (ESMO) again do not clarify the 
surgical staging in patients with intermediate risk endometrial cancer [25]. 
This controversial issue is likely to be concluded by the universal use of SLN mapping 
in supposed intermediate or high-intermediate patients. Currently, almost all guidelines agree 
that SLN mapping can be considered as an alternative to full lymphadenectomy, when a strict 
surgical algorithm is applied [79]. 
Prospective clinical trials (SENTI-ENDO and FIRES) have established that the method is 




SLN in endometrial cancer was first described by Thomas Burke of M D Anderson 
Cancer Center in 1996 [104]. His group first described 15 patients having the fundus injection 
of blue dye. A detailed algorithm was then developed by the group of Abu-Rustum from 
Memorial Sloan Kettering Cancer Center in New York (USA) [105, 106]. 
A recent meta-analysis reported overall detection rates higher than 80%, with 50% 
bilateral pelvic node detection rate and 17% para-aortic detection rate. The sensitivity of 
sentinel lymph node mapping to detect metastases is higher than 90%, reaching almost 100% 
in this meta-analysis. These low false-negative rates are comparable to those observed in 
breast cancer (10%) and vulvar cancer (8%), in which SLN is an accepted staging modality 
[107]. 
Multiple tracers and their combinations have been used in order to increase the 
detection rate. According to the present literature it seems that the Indocyanine green (ICG) 
or the combination of TC 99 and blue dye have the highest detection rate, usually higher than 
90% and 80% for bilateral detection [108]. The recently published FILM (Fluorescence Imaging 
for Lymphatic Mapping) prospective randomised study, compared the detection rate using 
ICG or blue dye. The results were in favour of the ICG tracer [109]. The authors suggested that 
the use of blue dye alone should not be implemented for SLN mapping purposes. In addition, 
the use of ICG is especially useful in obese patients [110]. Figure 5 represents examples of blue 
dye and ICG tracer. 
 
Figure 5. Pelvic sentinel lymph node traced with patent blue (left) and indocyanine green (right). 
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As far as the injection site is concerned, the majority of authors recommend the 
cervical injection, superficial and deep at 3 and 9 hours, easily accessible and reproducible 
[111]. Recently a dual injection has also been studied. It consists of deep fundus transvaginal 
application and cervical injection. It seems that the use of these method increases the aortic 
SLN detection. The importance of this finding needs further studies [112]. 
A learning curve, self-validated by monitoring the detection rate, is necessary, when 
introducing the SLN technique. All the SLN should be removed with macroscopically or 
radiologically suspected nodes. 
Frozen section examination can be performed by an expert pathologist and is 
sufficiently reliable to guide further staging [113]. 
There is no consensus on the value of a complete lymph node dissection in the 
presence of a positive pelvic sentinel node. The OSNA technique has been evaluated but 
cannot be used in everyday practice due to false positive cases. [114, 115]. 
SLN must be subjected to serial sections and immunohistochemistry stains to 
cytokeratin (AE3 and AE 4). The objective of this ultrastaging procedure is to discover low-
volume metastatic disease whose frequency is not negligible [100]. 
Classically the lymph node metastases are classified by their size [116]. 
Micrometastases range in size between 0.2 and 2 mm and isolated tumor cells are described 
as clusters of malignant cells less than 0.2 mm in dimension. While it is possible to identify 
previously undetected disease with these novel techniques, it is unknown if this low-volume 
disease is clinically significant. A study on a large series of patients with low-risk features 
demonstrated that use of ultrastaging doubled the identification of positive lymph nodes from 
2.6% to 5.9% [117]. However, retrospective data showed that detection and treatment of 
isolated tumor cells may not have any impact on patient’s survival [118]. Contrary, there is 
evidence to support the treatment of micrometastases in a similar manner to 
macrometastases [119]. 
Finally, the value of SLN is indisputable. Its safety, accuracy and prognostic information 
support its universal use in patients with intermediate risk endometrial cancer. 
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III. JUSTIFICATION OF THE PROJECT 
 
Management of women with early-stage endometrial cancer is still controversial and 
practice routine differs among gynecologic oncologists, countries and continents. The 
controversies are focused on intermediate risk endometrial cancer. This is principally because 
there are diverse criteria defining intermediate risk groups for recurrence, non-standardised 
protocols for surgical staging and different indications for adjuvant therapies. 
We have earlier addressed the issue of intermediate risk in a research work based on 
an earlier version of the risk classification [88]. It seemed necessary to reassess the clinical 
significance of the more recent stratification, with the introduction of a high-intermediate risk 
classification, since there are no studies giving strong evidence that the subclassification in 
two specific risk groups is relevant in real life clinical context [29]. 
Consequently, we carried out a study comparing the intermediate risk with high-
intermediate risk endometrial cancer (according to ESMO/ESGO/ESTRO 2016 classification) 
regarding nodal metastases rate and oncologic outcome. 
 
IV. HYPOTHESIS 
The new risk classification for early-stage intermediate risk, including the high-
intermediate risk endometrial cancer could better predict the lymph node involvement and 
oncological outcome than the old classification, allowing a more accurate tailoring of both 
surgical and adjuvant treatments. It would imply that the new subdivision would show 






The primary aim of the study was to evaluate the oncological outcome according to 
the current European intermediate risk subclassification of endometrial cancer by comparing 
the disease-free and overall survival in patients with intermediate and high-intermediate risk 
endometrial cancer. 
SECONDARY 
1- To compare lymph node involvement in intermediate and high-intermediate risk 
endometrial cancer. 
2- To analyze the predictive factors of lymph node involvement among the new risk 
groups. 
3- To analyze the factors associated with recurrence and death in intermediate and 




VI. MATERIAL AND METHODS 
We conducted a multicenter retrospective study at 4 tertiary Spanish institutions and 
one French Comprehensive Cancer Center. Data collection included the period from January 
2000 to December 2018. One thousand eight hundred sixty-four patients with endometrial 
cancer were recorded in a database. Only patients who underwent hysterectomy with nodal 
assessment, either full lymphadenectomy or sentinel lymph node biopsy were included in the 
study. Patients with FIGO stage II, IIIA, IIIB and IV were excluded. The data of patients with 
FIGO stage IIIC were incorporated in order to assess the risk of nodal metastases. Patients with 
FIGO stage IIIC and either one (or more) of the following: cervical stromal invasion, adnexal 
invasion, uterine serosa invasion were excluded. Out of 576 patients, 99 were excluded due 
to cervical, adnexa, serosa, parametrial, vesical involvement or metastatic disease. A sample 
of 477 patients with uterine characteristics of intermediate risk endometrial cancer on 
definitive pathology, according to the guidelines of the ESMO/ESGO/ESTRO 2016 were 











Figure 6. Patients’ selection chart. 
1864 Endometrial cancers 
• 40 no hysterectomy 
• 636 No lymph node evaluation 
• 612 low or high risk endometrial cancer 
• 58 cervical involvement 
• 16 adnexa involvement 
• 4 serosa involvement 
• 11 parametrial involvement 
• 1 Vesical involvement 
• 5 pelvic metastases 
• 4 extra‐pelvic metastases 
477 Intermediate risk endometrial cancer 
• 325 Intermediate 
• 152 High‐Intermediate 
576 Intermediate risk endometrial cancer 
• Endometriod G1‐2 and <50% myometrial invasion 
• Endometriod G1‐2 and LVSI 
• Endometrioid G3 and ≥ 50% myometrial invasion 
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The intermediate risk subclassification was defined as endometrioid histology with 
myometrial invasion ≥50%, grades 1–2 and negative LVSI. Patients with grade 1–2 tumours 
with LVSI unequivocally positive regardless the depth of myometrial invasion, and those with 
grade 3 tumours with <50% myometrial invasion regardless of LVSI status were categorized as 
high-intermediate risk (Table VI). 
Intermediate risk Endometrioid histology  
grade 1–2 and negative LVSI with myometrial 
invasion ≥50% 
High-intermediate risk Endometrioid histology  
grade 1–2 tumours with LVSI unequivocally positive 
regardless the depth of myometrial invasion,  
grade 3 tumours with <50% myometrial invasion 
regardless of LVSI status 
Table VI. Definition of Intermediate and high-intermediate according to ESGO/ESMO/ESTRO 2016. LVSI 
(Lymphovascular space invasion). 
Both intermediate risk groups were compared as to risk of nodal metastases, disease-
free and overall survival. Other patient´s and tumor´s characteristics (grade, myometrial 
invasion, histologic subtype, maximal tumor size), and adjuvant treatment were recorded. 
The protocol of the study was submitted and approved by the Hospital Clínico San 
Carlos Institutional Review Board (approval number C.P ISM-200503-C.I. 20/407-E) as Spanish 
reference center and ratified at the remaining Spanish institutions. The samples from the 
French tumor archives were centralized in the Biological Resources Centres of Institut 
Bergonié, which the French authorities authorized for scientific research. 
All patients underwent hysterectomy with bilateral salpingo-ooforectomy. 
Lymphadenectomy or sentinel lymph node biopsy were performed at institution discretion 
based on surgical team experience and institutional protocols. The same oncological team in 
each center performed all surgical interventions. Sentinel lymph node biopsy was detected 
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with combined method: blue dye and radiocolloid tracer and more recently with fluorescence 
imaging using indocyanine green tracer. 
Route of surgery (open or minimally invasive) depended on the surgical team and 
institution experience. In one center also robotic surgery as a minimally invasive approach was 
used. 
Preoperatively, mechanical bowel preparation could be carried out, and prophylactic 
antibiotics and low molecular weight heparin always administered. Intravenous fluids were 
maintained until patients tolerated oral fluids, usually within first 24 hours after the surgery. 
Foley catheter was usually removed the day after the surgery. Serum hemoglobin levels were 
routinely obtained within 24 hours after the procedure. Patients were discharged home if they 
demonstrated ability to ambulate independently, tolerated a regular diet, had stable vital 
signs and pain was under control. 
All the pathological specimens were analysed by expert pathologists dedicated to 
gynecologic oncology. Hysterectomy specimen were oriented, then opened and the tumor 
was measured in the largest dimension. A sample sections per centimeter of the largest tumor 
dimension were submitted to microscopical examination. The pathological reports included 
information about histologic type of tumor and histologic grade. Myometrial thickness, 
information about the presence of myometrial invasion and its depth was also reported. 
Information about uterine serosa involvement, lower uterine segment Involvement, cervical 
stromal involvement, parametrial and vaginal involvement were noted. All reports included 
information about lymphovascular space invasion, defined as at least one identified focus of 
lymphatic, vascular invasion, or lymphovascular invasion. Number of lymph nodes and 
positive lymph nodes were detailed as well. 
TNM staging system for endometrial cancer and FIGO were both used as pathologic 
stage classifications. 
Even though there are no controlled studies to support follow-up of patients once the 
treatment is completed, the follow up visits have been performed every 3-6 months up to 5 
years and then every 6-12 months up to 10 years. Each visit included physical examination and 
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pelvic ultrasound. Chest x-ray, computerized tomography or other more specific tests were 
recommended according to clinical findings. Patients have been informed about the need to 
consult in case of abnormal vaginal bleeding, abdominal distention, persistent pelvic pain, 
fatigue, persistent constipation and unexplained weight loss. 
The presence of recurrence, type of therapies, and patient status at last contact were 
collected during the patient’s follow-up. Time to relapse, and type and pattern of recurrence 
were collected. Recurrence was confirmed by biopsy or unambiguous imaging. 
Patients were managed following the guidelines approved by the European Society of 
Gynecology Oncology and Spanish Society of Obstetrics and Gynecology. 
The data were centralised in an encrypted database which is in propriety of Women’s 
Health Institute of the Hospital Clinico San Carlos located at Profesor Martín Lagos Street, 
28040 Madrid, Spain. 
Statistical analysis  
For continuous variables 
Continuous variables were expressed as mean and standard deviation. Kolmogorov-
Smirnov test was used to assess the normal distribution. To analyze the association between 
a continuous variable and a qualitative variable with two categories T-test was used in normal 
distributions or the Mann-Whitney test in non-parametrical distributions. To analyze the 
association between a continuous variable and a qualitative variable with three or more 
categories we used the ANOVA or Kruskal-Wallis test. 
For qualitative variables 
Qualitative variables were expressed with absolute frequencies and percentages. 
Comparison between two qualitative variables was made by a chi-squared test. In case of 




For survival analysis 
Tumoral recurrence was the dependent variable to assess the disease-free survival. 
The time to analyze this variable was the result of measure the time between the definitive 
surgery and the first evidence of recurrence. 
Decease due to tumor, for other causes or unknown was considered as dependent 
variable to assess the overall survival. The time to analyze this variable was the result of 
measure the time between the definitive surgery and the decease or the patient`s last contact. 
The Kaplan–Meier method was used to estimate the survival distribution in the study 
groups. The Log-rank test was used to calculate the statistical signification between the groups 
in relation to disease-free and overall survival. 
Mantel-Cox´s method was used to identify the factors directly associated with DFS or 
overall survival. In that cases the dependent variables were recurrence and death. 
Multivariate modeling using Cox’s proportional hazard models was performed to obtain a 
subset of independent predictors of disease-free and overall survival. We included in the 
multivariant model the variables associated to recurrence or death in Cox univariate analysis. 
Hazard ratios with 95% confidence interval were calculated. 
All statistical tests were two-sided and statistical significance was defined as p value 














Figure 7. High-intermediate and intermediate risk study group. 
A total of 477 patients with intermediate risk endometrial cancer at definitive 
pathology and who had nodal assessment were included. Of these, 325 (68%) patients were 
identified as intermediate risk and 152 (32%) patients as high-intermediate risk (Figure 7). 
Both groups were similar in baseline characteristics (age, body mass index, comorbidities). The 
median age of the total cohort was 66 years (range, 31-89). Three hundred eighty-seven 
patients (81.2%) received adjuvant treatment, including brachytherapy (195 patients), 
external beam radiotherapy (166 patients), and irradiation and chemotherapy (26 patients). 
Patients’ characteristics are presented in Table VII. Comparison of selective features of 
intermediate risk and high-intermediate risk group is represented in Figure 8. 
  













Age (years) 66.4 ± 9.1 65.1 ± 9.8 0.153 
BMI (kg/m2) 29.8 ± 5.7 28.8 ± 5.4 0.077 
Associated diseases †  214 (65.8) 91 (59.9) 0.205 
Years from menopause  16.3 ± 9.6 15.1 ± 10.2 0.288 
Parity 1.9 ± 1.5 1.9 ± 1.3 0.767 
Pre-surgical hemoglobin (mg/L) 13.5 ± 1.1 13.4 ± 1.4 0.597 
Histologic subtype 
• Pure endometrioid  
• With mucinous differentiation 
























• < 50% 





















Tumor size (cm) 3.0 ± 1.5 3.3 ± 1.7 0.046 
Surgical approach 
• Laparotomy 









• Pelvic only 








Nº nodes removed 
• Pelvic 
• Pelvic and para-aortic 
 
14.1 ± 7.4 
12.2 ± 10.0 
 
14.1 ± 6.7 















Adjuvant Treatment  
• None 
• Brachytherapy 
• External beam radiation 













Length of follow-up in months 60.1 ± 40.4 48.8 ± 33.5 0.001 
 
Table VII. Patient demographics and pathologic details in intermediate risk endometrial cancers. Data are shown 
as mean ± (standard deviation) or cases (%). BMI: Body Mass index. ASA: American Society of Anesthesiologist. 
*t test in variables with normal distribution, Mann-Whitney test for the others continuous variables and chi2 test 





Figure 8. Comparison of intermediate risk and high-intermediate risk group (%). 
Thirty-four patients (7.1%) were found to have lymph node metastases in the entire 
group. In the intermediate risk group 16 patients (4.9%) had lymph node metastases. Nodal 
disease was found in 18 (11.8%) patients with uterine characteristics of high-intermediate risk 
endometrial cancer. The difference was statistically significant (p=0.006). LVSI was the only 
independent pathological feature associated with lymph node involvement (p<0.001). The 









Minimally invasive approach Paraaortic Lymphadenectomy Positive lymph nodes
%
Tytuł osi





Variables No lymph node 
metastases N=443 
Lymph node metastases 
N=34 
P value* 
Age (years) 66.2 ± 91 63.1 ± 11.3 0.056 
Histologic subtype 























• < 50% 








Maximum tumor size (cm) 3.1 ± 1.6 3.4 ± 1.5 0.381 





















Table VIII. Predictive factors of lymph node metastases in 477 cases of intermediate risk endometrial cancers. 
Data are shown as cases (%) and mean ± standard deviation. LVSI (Lymphovascular space invasion). 
*Only patients with known LVSI status were included in the statistical analysis. 
 
After a median follow up of 53.2 months [interquartile range, 25.9-86.9], 53 (11%) 
patients recurred, 29 (8.9%) patients in the intermediate group and 24 (15.8%) patients in the 
high-intermediate risk group. The distribution of recurrences was significantly (p=0.024) 
different between groups, with 10 pelvic recurrences (34.5% of recurrences), 2 nodal 
recurrences (6.9%), and 17 distant recurrences (58.6%) in the intermediate risk group 
compared to 3 pelvic (12.5%), 8 nodal (33.3%) and 13 distant (54.2%) in the high-intermediate 
risk group. Interestingly, nodal recurrence rate occurred in 0.6% of patients in intermediate 
risk patients versus 5.2% in the high-intermediate group. 
Twenty-seven patients (5.6%) were alive with disease. A total of 47 (9.8%) patients 
died and, of these, 27 patients died of disease. Cancer related deaths were more common in 
the high-intermediate group, 15 (9.8%) patients versus 13 (4%) patients in the intermediate 
group, but this finding did not reach the statistical significance (p=0.056) (Table IX). 










Recurrence 29 (8.9) 24 (15.8) 0.026 











Decrease 28 (8.6) 19 (12.7) 0.173 
Cause of decrease: % from recurrences  
• Dead for tumor 
• Dead for other causes 









Table IX: Recurrence and mortality in 477 intermediate risk endometrial cancers. Data are shown as cases (%). 
*Recurrence in nodes as first localization. 
†Recurrence in two or more sites, or distant metastases. 
 
 
Figure 9. Oncological outcome of intermediate and high-intermediate risk. 
Five-year disease-free survival was 90.7% in the intermediate risk group versus 79.5% 
in the high-intermediate risk group (p=0.006). Five-year overall survival was 92.5% in the 
intermediate group and 83.7% in the high-intermediate risk group (p=0.042). Disease-free and 
overall survival were significantly lower in the high-intermediate group with hazard ratio 2.10 












Oncological outcome of intermediate and high-
intermediate risk
Intermediate Risk High-Intermediate Risk
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(95% confidence interval 1.22-3.62; p=0.009) and hazard ratio 1.82 (1.01-3.28; p=0.045), 
respectively (Figure 10). 
In the univariant analysis high-intermediate risk was an independent factor of disease-
free (hazard ratio: 2.10, 95% confidence Interval: 1.22-3.62; p=0.009) and overall survival 
(hazard ratio: 1.82; 95% confidence Interval 1.01-3.28; p=0.045). Lymph node involvement 
was also identified as a factor of recurrence (hazard ratio: 3.68, 95% confidence interval: 1.84-
7.36; p<0.001) and death (hazard ratio: 2.36, 95% confidence interval: 1.00-5.57; p=0.050) 
(Table X). 
 
 Disease-free survival  Overall Survival  
 HR (95% CI) p value HR (95% CI)  p value 
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Table X. Univariate analysis of disease-free survival and overall survival in 477 intermediate risk endometrial 






Figure 10 A, B: Kaplan-Meier estimate of disease-free survival and overall survival in intermediate and high-
intermediate endometrial cancer respectively. 
 














The multivariate analysis found that high-intermediate risk was an independent factor 
of disease-free survival (adjusted hazard ratio: 1.86, 95% confidence Interval: 1.02-3.39; 
p=0.043) and overall survival (adjusted hazard ratio: 1.99; 95% confidence Interval 1.10-3.60; 
p=0.022). In addition, lymph node involvement was also identified as an independent factor 
of recurrence (hazard ratio: 3.06, 95% confidence interval: 1.39-6.72; p=0.005). When risk 
stratification, was removed from the model, age (hazard ratio: 1.04, 95% confidence Interval: 
1.01-1.07; p=0.038) and LVSI (hazard ratio: 1.93, 95% confidence Interval: 1.01-3.73; p=0.049) 
were found to be independent factors for disease-free survival (Table XI). Kaplan-Meier 
estimate of disease-free survival and overall survival for patients with different 
lymphovascular space invasion and lymph node status are represented in Figures 11-14. 
 
 
 Disease-free survival  Overall Survival  
 HR (95% CI) p value HR (95% CI)  p value 











































Table XI. Multivariate analysis of disease-free survival and overall survival in 477 intermediate risk endometrial 
cancers. HR= Hazard Ratio. CI = confidence interval.  
 * Lymphovascular space invasion is a significant variable when risk stratification is removed from the model, as 












































Figure 13. Impact of Lymphovascular space invasion (LVSI) on disease-free survival. 
 
 
















Our study shows that the current European risk stratification is effective in defining the 
risk of lymph node disease and prognosis in intermediate risk group. The subclassification of 
risk into standard intermediate and high-intermediate has been validated in our series. Within 
the wider intermediate risk group, patients have different risk of nodal disease and different 
prognosis. The current subclassification partially reflects and reduces this heterogeneity. The 
prevalence of nodal disease is significantly higher and nodal recurrences are more frequent in 
the high-intermediate group. Prognosis is substantially poorer in high-intermediate risk cancer 
patients. The former intermediate risk endometrial cancer is therefore not a homogeneous 
group, and the subclassification is fully justified to guide adjuvant therapy. 
The risk classifications substantially changed in the last 20 years. The definition of 
intermediate risk and high-intermediate risk endometrial cancer is not universal. These 
differences in definition make it difficult to extrapolate the results of studies addressing the 
prognosis of intermediate low and high risk endometrial cancer patients. 
One study compared the accuracy of five major risk stratification systems in classifying 
the risk of recurrence and nodal metastases in early-stage endometrial cancer. The authors 
found that none of the five major risk stratification systems showed high accuracy in stratifying 
the risk of recurrence or nodal metastases in patients with early-stage endometrial cancer, 
although the current European classification emerged as having the highest power of 
discrimination [28]. 
Our study suggests that the current European risk stratification is effective in defining 
the risk of lymph node disease and prognosis. To our knowledge this is the first study that 
evaluates the role of the subclassification of intermediate risk endometrial cancer in a large 
multicentric cohort with multivariate analysis. 
In relation to our results, it remains necessary to discuss in what regard they are 
relevant for clinical practice. Without any doubt, the finding of high-intermediate features at 
definitive pathology orientates state-of-the-art adjuvant treatment, and forms the basis of 
future clinical trials. 
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However, there are still several clinically relevant topics open for in depth discussion. 
First, the preoperative risk assessment is incomplete or inaccurate in several regards: the LVSI 
status is unknown before definitive pathology of the operating specimen, the pathologic 
grading on endometrial biopsy specimens may not reflect the final pathology and the 
estimation of myometrial invasion by imaging may be inaccurate. 
The preoperative work-up using diagnostic pathology examination and radiological 
assessment may fail in nearly 40 % of cases. In consequence, this may lead to suboptimal initial 
surgical management of patients with endometrial cancer. 
Histotype and grade, key parameters in the classical stratification systems of 
endometrial cancer, have been shown to have important rate of preoperative misdiagnosis.  
The most widely used histologic grading system for endometrial carcinoma is the 
three-tiered FIGO classification. Based on the data presented by Creasman the frequency of 
pelvic lymph node metastases is found in 3%, 9%, and 18% in grade 1, 2, and 3 endometrial 
cancer and of para-aortic involvement 2%, 5%, and 11% in grade is 1, 2, and 3, respectively 
[50]. Erroneous preoperative grade assessment count for 30-40% when compared with final 
histology [120]. 
In order to unify the classification, a binary grading system (high grade/low grade) was 
proposed based on the amount of solid growth, the pattern of myometrial invasion, and the 
presence of tumor cell necrosis. The interobserver agreement of both systems was analysed 
in several studies finding at first promising results that were finally not confirmed in further 
studies [121-124].  
However, the overall reported reproducibility using the FIGO system is 64.5-70% [80, 
84]. In some publication concordance for grade 3 tumors was significantly higher than that for 
grade 1 or 2 [125, 126]. 
An interesting publication by Eltabbakh et al. found that approximately 30% of women 
with endometrial carcinoma whose preoperative endometrial biopsy shows grade 1 tumors 
have grade 2 or 3 in the hysterectomy specimen [120]. 
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The reproducibility of diagnosis of endometrial hyperplasia, atypical hyperplasia and 
well-differentiated carcinoma were also assessed in several studies. The reported results show 
that the interobserver agreement ranges from 76% to 89% [54, 55, 127-129]. 
Erroneous pathological diagnosis may lead to suboptimal initial surgical management 
of patients with endometrial cancer. Therefore, some authors recommend to always perform 
a full staging procedure regardless the initial preoperative grade and stage [130]. 
Interestingly the concordance in molecular tumor alterations between preoperative 
(hysteroscopy, curettage) and postoperative (surgical specimen) findings is high [131, 132]. 
Preoperative evaluation of endometrial cancer using modern imaging methods is 
another element, universally recommended before surgical treatment. Out of possible 
imaging methods magnetic resonance imaging (MRI) used to be described as the most 
accurate in describing local-regional stage of endometrial carcinoma. MRI is superior to 
computed tomography for visualizing uterine and pelvic tissues. [133-135]. 
However, more recent works, like those from Prague group led by Daniela Fischerova, 
report comparable accuracy of ultrasound to that of MRI in depicting myometrial and cervical 
infiltration by endometrial cancer when performed by an expert [136]. 
The group from Prague established a detailed ultrasound protocol to correctly assess 
stage of endometrial cancer. These authors report underestimation of myometrial invasion in 
8.6%. Cervical Stromal invasion was underestimated in 10.5% of cases. Myometrial invasion 
was overestimated in 15.7% cases, and cervical invasion in 4.8%. The global accuracy in this 
study was influenced by tumor size, density of tumor vascularization, tumor vessel 
architecture and histological grading, while it was not significantly affected by BMI, uterine 
position and image quality [136]. 
Revision of the FIGO staging system in 2009 simplified stage I disease to only two 
categories (i.e. FIGO stage IA: no or less than half myometrial invasion; FIGO stage IB: invasion 
equal to or more than half of the myometrium) and left only cervical stromal invasion as a 
distinct stage (FIGO stage II), while endocervical glandular involvement only should be 
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considered as FIGO stage I and no longer as stage II. The simplified FIGO staging system may 
have contributed to higher preoperative diagnostic accuracy [137, 138]. 
In order to overcome the discordance between the preoperative and definitive 
pathological assessment, some authors proposed intraoperative evaluation of myometrial 
invasion performed as gross or frozen section examination. The intraoperative evaluation of 
myometrial invasion and grade lead the surgical decision whether to perform or not a full 
staging procedure. The supporters of this method point out its low cost and accuracy when 
perform by an experienced pathologist. In a recent study published by an Italian group the 
concordance rate between myometrial invasion in frozen section and final pathology was 
89.1%. The same study shows accuracy of intraoperative grading in 91% of cases. The authors 
finally suggest to use frozen section examination only in ambiguous or inconclusive 
preoperative diagnosis [139]. 
These data are not confirmed in different studies that report 30-60% of grade 
agreement and important underestimation of myometrial invasion agreement [140-143]. 
In this regard macroscopic of myometrial/cervical invasion may be challenging 
especially in small, low grade tumors as the invasion line can be heterogeneous or skip 
metastasis may be present. 
The idea of frozen section examination has not been retained in the last 
ESGO/ESMO/ESTRO recommendations. This opinion is supported by groups of pathologists, 
who underline the importance of artefact generated during frozen section examination, that 
interferes with an optimal pre-analytical procedure required for standardized 
histopathological diagnosis [143]. 
On the other hand, LVSI status cannot be established at all in the preoperative setting. 
In other words, the LVSI status component of the ESGO/ESMO/ESTRO classification cannot be 
used to indicate lymph node dissection. 
However, as already mentioned, there is no definitive evidence that lymphadenectomy 
has a therapeutic value. Available randomised data on lymph node dissection did not show 
any survival benefit in patients with low and intermediate/high risk endometrial cancer while 
impacting morbidity [41, 42]. 
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The finding of our study is that the risk of lymph node involvement in the standard 
intermediate group is low, with consequently no obvious benefit of lymph node dissection. 
While the higher risk in the high-intermediate group, with consequently a potential yield, 
influence on adjuvant treatment, and therapeutic impact of lymph node dissection, makes the 
question of performing or not a node dissection in presumed intermediate risk is a very 
difficult one. The point is then to decide on the basis of relatively inaccurate stratification, or 
to find a midterm between no node dissection and complete node dissection. Taking into 
consideration the difficulty in assessing LVSI preoperatively and the controversy regarding full 
lymph node dissection, the current development of the SLN technique is likely to be the best 
staging compromise in intermediate risk cancer patients [119]. Prospective clinical trials 
(SENTI-ENDO and FIRES) have established that the method is safe and associated with a lower 
rate of complications than standard lymphadenectomy [100-102]. 
The paradigm of lymph node dissection continues to be challenged. Adjuvant 
treatment can potentially be guided only by uterine pathologic features and recently 
introduced molecular markers based on the Cancer Genome Atlas Research Network data 
[12]. Molecular characteristics have already been incorporated in the NCCN guidelines 
algorithms [30]. In addition, L1 cell adhesion molecule (L1-CAM) was found to be an 
independent marker of distant recurrence and overall survival [16]. 
Awaiting the results of PORTEC 4A study, the current subclassification of intermediate 
risk has to be taken into account for adjuvant treatment planning. The same will remain valid 
in the future in settings where molecular biology resources are not available. In addition, the 
therapeutic role and the modalities of adjuvant treatment in endometrial cancer is also 
controversial. The publications of the PORTEC group question the prognostic value of external 
beam radiotherapy [27]. PORTEC 2 study compared vaginal brachytherapy versus external 
beam radiotherapy for patients with high-intermediate risk endometrial cancer (PORTEC risk 
stratification) and found no difference in disease-free survival. Toxicity and quality of life 
profile were more favourable in the brachytherapy arm [44]. Based on these finding, the 
European consensus panel recommends external beam radiotherapy only in the subgroup of 




METHODOLOGICAL ISSUES AND REMAINING UNANSWERED QUESTIONS 
The main weakness of this study is its retrospective nature. Consequently, conclusions 
about the impact of adjuvant treatment cannot be drawn, as clinical protocols changed along 
years and differed across the centres. The introduction of adjuvant treatments in this model 
cannot be relevant. This bias is only partially controlled by multivariant character of statistical 
study. This study could though be a basis for a prospective, multicentric project with 
standardised criteria for adjuvant treatment and pathological analysis with centralized review. 
Another methodological weakness could be related to the lack of power of the study. 
Lymph node involvement was identified as a significant independent factor of recurrence but 
not for overall survival. It is likely but not demonstrated, that the same figures would become 
significant with larger sample size. In spite of these reservations, it remains that the 
multivariate analysis found high-intermediate risk to be a significant, independent factor of 
disease-free and overall survival, which was the primary objective of this study. 
In addition, we had to remove the risk stratification from the multivariate analysis in 
order to identify the significant prognostic value of LVSI. This decision was justified by the fact 
that LVSI is included in the definition of the majority of high-intermediate risk cases, 
generating redundant information. 
Another issue is that the extent of LVSI (focal or extensive), a relatively recently defined 
distinction, was not recorded in our pathological records. Moreover, centralized pathology 
review, comparison between centres and quality control between pathologists were not 
performed. Mention of LVSI when only focal disease was found may potentially have led to 
inappropriately allocating patients in the high-intermediate risk group, and incorrectly 
improve the prognosis of this group of patients, decrease the rate of lymph node involvement 
and expose those patients to unnecessary adjuvant treatment. However, this does not impact 
the conclusions of this study, as it is likely that not including focal LVSI would have reinforced 




A criticism about the absence of routine para-aortic lymph node dissection in our study 
could also be raised. However, the risk of isolated aortic node disease when the pelvic nodes 
are negative is negligible [50]. Even if the risk of aortic lymph node involvement is high when 
pelvic nodes are positive, there is no evidence that systematic para-aortic lymph node 
dissection improves survival.  
FUTURE PERSPECTIVES 
Still many questions require an answer: do we really need the lymph node status to 
make a decision on adjuvant treatment? Would it be detrimental for our patients to omit 
lymphadenectomy, if the preoperative record is negative? Isn’t it more detrimental to perform 
a full staging knowing the chance of short- and long-term complications? The results of our 
study are in favor of some form of lymph node assessment, given the high rate of node-
positivity in high-intermediate risk patients. However, the low rate of lymph node involvement 
in low intermediate risk patients does not justify the full lymph node dissection with its short 
and long-term complications. As the high intermediate risk is known only after definitive 
pathology, sentinel lymph node biopsy in all patients seems to be a reasonable compromise. 
However, this assumption needs to be confirmed in prospective trials. 
The results of ECLAT prospective trial will be crucial to find the definitive answer 
about the utility of para-aortic lymph node dissection in endometrial cancer patients. The 
answer is expected to arrive by 2028. If this study is negative, possibly ‘’la belle époque’’ of 
lymphadenectomy in endometrial cancer as a standard procedure of every gynecologic 
oncologist could be ended. 
Meanwhile, the molecular classification could open new perspectives in treatment of 
endometrial cancer. Its universal use in pre- and postoperative setting could potentially 
conclude for always the controversy around lymph node dissection. 
It is possible that individualised treatment could be a perfect answer in the 
management of endometrial cancer patients. Choice of the best therapy could be guided by 
tumor pathological and molecular characteristics, SLN status, but also patient’s 
characteristics. Age and risk of death due to other pathologies should be taken into account. 
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The individual decision of the patients about the treatment preventing relapse could also be 
an important item when planning adjuvant treatment. The idea of use of artificial intelligence 
algorithm in taking this decision could be revolutionary. This philosophic and futuristic 




VIII. CONCLUSIONS (ENGLISH) 
 
• Disease-free and overall survival of high-intermediate risk endometrial cancer 
according to current European intermediate risk subclassification is significantly 
poorer when compared to intermediate risk endometrial cancer. 
• Lymph node involvement is significantly higher in high-intermediate risk group when 
compared to intermediate risk group and was an independent factor of recurrence. 
• Lymphovascular space invasion is the most important predictive factor of lymph node 
disease. 
• The age and presence of lymphovascular space invasion are found to be independent 
factors associated with recurrence in the whole group of intermediate risk endometrial 
cancer.  
• The age and high-intermediate risk were independent variables of mortality in the 





• Las pacientes con cáncer de endometrio de riesgo intermedio-alto, según la 
subclasificación europea actual, presentaron una supervivencia libre de enfermedad y 
una supervivencia global significativamente peores en comparación con las pacientes 
con cáncer de endometrio de riesgo intermedio. 
• La afectación ganglionar es significativamente mayor en el grupo de riesgo intermedio-
alto en comparación con el grupo de cáncer de endometrio de riesgo intermedio. 
Además, esta afectación ganglionar es un factor de riesgo independiente para la 
recurrencia de la enfermedad. 
• La invasión linfovascular es el factor predictivo más importante asociado con la 
afectación ganglionar linfática. 
• La edad y la presencia de la invasión linfovascular son factores de riesgo 
independientes asociados con la aparición de recurrencias en las pacientes con cáncer 
de endometrio de riesgo intermedio de modo general.  
• La edad y las características tumorales de riesgo intermedio-alto fueron las variables 
independientes de supervivencia global en las pacientes con cáncer de endometrio de 
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